+Vote!
Market Wire - Pharmaceuticals and Biotech (Free subscription) | 11/10/2008
SOUTH SAN FRANCISCO, CA (MARKET WIRE) Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that it has filed a shelf registration statement on Form S-3 with the U.S. Securities and Exchange Commission (SEC). The shelf registration statement, if declared effective by the SEC, will allow the Company to raise up to $100 million through the sale of securities, which may consist of common stock,...
+Vote!
bizjournals (Free subscription) | 11/10/2008
Cytokinetics Inc. said Monday it may raise up to $100 million through the sale of securities such as stock and warrants. (CYTK)
+Vote!
Market Wire - Pharmaceuticals and Biotech: Biotech (Free subscription) | 11/03/2008
SOUTH SAN FRANCISCO, CA (MARKET WIRE) Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that data relating to a Phase IIa clinical trial for CK-1827452 are scheduled to be presented during a Special Program at the 2008 Scientific Sessions of the American Heart Association which is being held November 8-12, 2008 at the Ernest N. Morial Convention Center in New Orleans, La. These data...
+Vote!
Market Wire - Pharmaceuticals and Biotech: Biotech (Free subscription) | 11/05/2008
SOUTH SAN FRANCISCO, CA (MARKET WIRE) Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present corporate updates at two investor conferences in November:
+Vote!
Red Orbit (Free subscription) | 11/04/2008
Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that data relating to a Phase IIa clinical trial for CK-1827452 are scheduled to be presented during a Special Program at the 2008 Scientific Sessions of the American Heart Association which is being held November 8-12, 2008 at the Ernest N.
+Vote!
The Earth Times Online Newspaper (Free subscription) | 11/03/2008
SOUTH SAN FRANCISCO, CA -- 11/03/08 -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that data relating to a Phase IIa clinical trial for CK-1827452 are scheduled to be presented during a Special Program at the 2008 Scientific Sessions ..
+Vote!
Market Wire - Pharmaceuticals and Biotech: Trials (Free subscription) | 10/30/2008
SOUTH SAN FRANCISCO, CA (MARKET WIRE) Cytokinetics, Incorporated (NASDAQ: CYTK), reported revenues from research and development collaborations of $3.1 million for the third quarter of 2008. The net loss for the three months ended September 30, 2008, which included $2.5 million in restructuring charges, was $16.3 million, or $0.33 per share compared to a net loss of $11.3 million, or $0.24 per...
+Vote!
Red Orbit (Free subscription) | 10/31/2008
Cytokinetics, Incorporated (NASDAQ: CYTK), reported revenues from research and development collaborations of $3.1 million for the third quarter of 2008.
+Vote!
Market Wire - Conference Calls (Free subscription) | 10/23/2008
SOUTH SAN FRANCISCO, CA (MARKET WIRE) Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that it is scheduled to report third quarter results on Thursday, October 30, 2008 at 4:00 p.m. Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 p.m. Eastern Time to discuss operational and financial results and the company's outlook...
+Vote!
Market Wire (Free subscription) | 10/23/2008
SOUTH SAN FRANCISCO, CA (MARKET WIRE) Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that three posters containing data on GSK-923295, an inhibitor of centromere-associated protein E (CENP-E), and one poster containing data on SB-743921, an inhibitor of kinesin spindle protein (KSP), were presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics held...
+Vote!
Red Orbit (Free subscription) | 10/24/2008
Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that it is scheduled to report third quarter results on Thursday, October 30, 2008 at 4:00 p.m. Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 p.m.
+Vote!
Market Wire (Free subscription) | 10/20/2008
SOUTH SAN FRANCISCO, CA (MARKET WIRE) Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that data relating to a Phase IIa clinical trial for CK-1827452 were presented during a Special Program at the 12th Annual Scientific Meeting of the Japanese Heart Failure Society, which was held October 16-18, 2008 at the Hotel Pacific Tokyo in Tokyo, Japan. These data represent an interim analysis...
+Vote!
Red Orbit (Free subscription) | 10/20/2008
Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that data relating to a Phase IIa clinical trial for CK-1827452 were presented during a Special Program at the 12th Annual Scientific Meeting of the Japanese Heart Failure Society, which was held October 16-18, 2008 at the Hotel Pacific Tokyo in Tokyo, Japan.
+Vote!
Market Wire (Free subscription) | 10/15/2008
SOUTH SAN FRANCISCO, CA (MARKET WIRE) Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that four posters containing data on GSK-923295, an inhibitor of centromere-associated protein E (CENP-E) and data on SB-743921, an inhibitor of kinesin spindle protein (KSP) are scheduled to be presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics to be held...
1Vote!
Red Orbit (Free subscription) | 10/16/2008
Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that four posters containing data on GSK-923295, an inhibitor of centromere-associated protein E (CENP-E) and data on SB-743921, an inhibitor of kinesin spindle protein (KSP) are scheduled to be presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics to be held from October 21-24, 2008 at the Geneva...
